Kenvue Inc. (KVUE) Stock Price & How to Invest

Kenvue is the world's largest pure-play consumer health company, spun off from Johnson & Johnson in 2023, and it is now in the process of being acquired by Kimberly-Clark, the maker of Huggies, Kleenex, and Kotex. The two companies signed a merger agreement on November 2, 2025 under which each Kenvue share is to be converted into $3.50 in cash plus 0.14625 of a Kimberly-Clark share, a combination valued at about $48.7 billion when it was announced. In October 2026 the European Commission approved the deal on condition that Kimberly-Clark sell its Kotex, Camelia, and Record feminine-hygiene brands in the European Economic Area (to Dilek Grup), and in August 2026 Kenvue agreed to sell its feminine-care business in Brazil to Essity for about $284 million, a sale Brazil's competition authority has cleared. On September 28, 2026 Kimberly-Clark launched exchange offers for up to $7.0 billion of Kenvue notes, conditioned on the merger, which it expects to complete in the fourth quarter of calendar 2026.

Until closing, Kenvue still operates its portfolio of over-the-counter and personal-care brands in three segments: Self Care (Tylenol, Motrin, Sudafed, Zyrtec, Benadryl, Nicorette, Imodium), Skin Health and Beauty (Neutrogena, Aveeno, OGX), and Essential Health (Listerine, Band-Aid, Johnson's baby products). It sells everyday, repeat-purchase health and hygiene products through pharmacies, mass retailers, grocery, and e-commerce, and makes money by using trusted brands and broad distribution to command premium pricing over private label. Trailing revenue is about $15.4 billion, and Q2 2026 revenue of about $3.96 billion grew roughly 3% year over year, with EPS of $0.31 against a $0.32 estimate. KVUE closed at $18.81 on October 16, 2026, up about 8.6% year to date and 33% over one year, for a market value near $36 billion. Because most of the consideration is Kimberly-Clark stock, the KVUE price now tracks KMB closely, and it inherits the litigation it carried from its J&J consumer heritage, which passes to the combined company at closing. Headquartered in Summit, New Jersey.

The main risks are now deal risks. Closing could be delayed or fail if remaining regulatory conditions are not met, and a failed deal would likely send KVUE back toward a standalone valuation. Because most of the consideration is Kimberly-Clark stock, a fall in KMB shares directly lowers what a Kenvue holder receives; Kimberly-Clark shares had fallen about 13% according to an October 2026 report. The combined company takes on Kenvue's inherited litigation, including Tylenol and talc-related claims, plus integration risk and added debt from the cash portion. Until closing, Kenvue's own operations still carry private-label competition, input-cost inflation, and currency exposure, and its latest quarter showed only about 3% revenue growth with EPS slightly below estimates.

12 analysts publish price targets on KVUE, averaging $19.50 against a $18.91 price as of October 2026, or +3.1%. The published targets run from $18.00 to $23.00, a narrow spread, and the ratings split 2 buy, 12 hold, 0 sell. Over the last six months there have been 2 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full KVUE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Kenvue Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. What holders receive at closing. Each Kenvue share is set to be exchanged for $3.50 in cash plus 0.14625 of a Kimberly-Clark share. The most optimistic published target, $23.00, assumes this works close to its best case.

The case against. The main risks are now deal risks. The most pessimistic target, $18.00, is roughly what KVUE is worth if this bites instead.

Read the full bull and bear case on KVUE, including what would have to change to break either one. Walnut is not an investment adviser.

No. Kenvue Inc. (KVUE) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Kenvue Inc.'s investor relations page or your broker.

• Deal consideration (per KVUE share): $3.50 cash + 0.14625 KMB shares
• Expected closing: Q4 2026 (per Kimberly-Clark)
• Revenue (TTM): ~$15.4 billion (Q2 up ~3% YoY)
• Net income (TTM): ~$1.66 billion
• P/E (trailing / forward): ~22x / ~15x
• Dividend yield: ~4.5%
• Market cap: ~$36 billion

Kenvue no longer trades on its own fundamentals: with a signed merger agreement and conditional EU approval, the KVUE price reflects $3.50 of cash plus 0.14625 of a Kimberly-Clark share, minus a discount for time and the chance the deal fails. The trailing and forward multiples above describe the business Kimberly-Clark is buying rather than what drives the stock day to day.

If you want KVUE exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to KVUE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get KVUE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (SDY), which spreads the position across many companies. Or build it into a focused thematic portfolio, so KVUE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where KVUE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Kenvue (KVUE) is a pending-acquisition stock: holders are set to receive $3.50 in cash plus 0.14625 Kimberly-Clark shares per Kenvue share when the deal closes, which Kimberly-Clark expects in the fourth quarter of 2026. In a portfolio it now behaves mostly like a partial Kimberly-Clark position plus cash, with the remaining questions being deal timing, the final regulatory steps, and Kimberly-Clark's own share price, rather than Kenvue's standalone growth or its roughly 4.5% dividend.

Whether KVUE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is KVUE a buy or a sell?, and where the stock could go from here in the KVUE stock forecast.

For income investors, whether KVUE pays a dividend and how the payout looks is covered in does KVUE pay a dividend? And to weigh KVUE against a peer, read the full side-by-side comparisons: KVUE vs HLN and KVUE vs PG.